Results 281 to 290 of about 180,585 (312)

Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens

European Journal of Pharmacology, 1993
In the electrically field-stimulated rabbit vas deferens, muscarinic receptor agonists increase twitch-height by actions at postjunctional M2 receptors and decrease twitch-height by actions at prejunctional M1 receptors. In the present studies, in contrast to previous reports, muscarinic receptor agonists primarily decreased twitch-height, produced ...
H E, Shannon, B D, Sawyer, K G, Bemis, F P, Bymaster, I, Health, C H, Mitch, J S, Ward   +6 more
openaire   +2 more sources

Clinical significance of M1 receptor antagonists.

Pharmacology, 1989
The M1-selective antimuscarinic drugs pirenzepine and telenzepine moderately reduce gastric acid secretion without inhibiting smooth-muscle activity as much as nonselective antimuscarinics, e.g. atropine and 1-hyoscyamine. They hasten peptic ulcer healing and improve the symptoms of reflux oesophagitis.
openaire   +1 more source

Muscarinic M1-Receptor Agonists

CNS Drugs, 1995
Neal R. Cutler, John J. Sramek
openaire   +1 more source

M1 Muscarinic Agonists Target Major Hallmarks of Alzheimer’s Disease – The Pivotal Role of Brain M1 Receptors

Neurodegenerative Diseases, 2008
The M1 muscarinic receptor (M1 mAChR) is a therapeutic target in Alzheimer’s disease (AD) and the M1-selective muscarinic agonists AF102B, AF150(S) and AF267B are cognitive enhancers and potential disease modifiers. Notably, AF267B decreased cerebrospinal fluid β-amyloid (Aβ₄₀ and Aβ₄₂) in rabbits ...
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

M1 receptor activities of substituted azaspirodecanones

Life Sciences, 1993
G Mullen, J Blosser, A Kover, J Loch, S McCreedy, A Machulskis, ESC Wu   +6 more
openaire   +1 more source